Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of biotech InterMune
So what: Germany's Federal Joint Committee has granted the additional benefit of Esbriet for treatment of idiopathic pulmonary fibrosis. The drug's benefit was classified as stage 4, which means its benefit isn't quantifiable yet, but will be defined more specifically in the future.
Now what: InterMune will now proceed to enter price negotiations with the entity that represents Germany's sickness funds, which are health insurance providers that cover the costs of drugs in the country. Baird has followed up the announcement by reiterating its outperform rating, and whopping $38 price target, which is more than double today's high. That price action isn't entirely unreasonable, as shares flirted with the $50 threshold roughly a year ago.
Interested in more info on InterMune? Add it to your watchlist by clicking here.
Fool contributor Evan Niu holds no position in any company mentioned. Click here to see his holdings and a short bio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.